Developing the First Defense

Aeolus Pharmaceuticals is developing its lead compound, AEOL-10150, as a treatment for the pulmonary and delayed effects of acute radiation exposure.

Learn More

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals development work is funded under a five year, $118 million, cost-plus contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, and funding from the National Institutes of Health (NIH) Learn More About Us ›

Clinical Data

AEOL 10150 has performed well in animal safety studies, been well-tolerated in two human clinical trials, demonstrated efficacy in two species in acute radiation syndrome (ARS) studies and demonstrated statistically significant survival efficacy in an acute radiation-induced lung injury model. Learn More About Us ›
Sign up for email alerts Be the first to receive breaking news Sign Up Today